Lundbeck A/S, which has a global franchise in drugs for the central nervous system, has acquired LifeHealth Ltd of the UK to increase its interest in the neurological drug, Xenazine (tetrabenazine), which was launched in the US in late 2008.
Novacta Biosystems Ltd, which is developing a class of naturally-derived antibiotics, will receive up to £13.1 million in equity financing for the development of its portfolio, provided certain undisclosed milestones are met.
Elan Corporation Plc has reached an agreement with Johnson & Johnson that will give the US multinational an 18.4% stake in the company as well as controlling interest in a new unit that will hold many of Elan’s assets in Alzheimer’s disease.
The UK government plans to invest £150 million in a small number of specialist technology funds, including those in the life sciences, in order to stimulate private venture capital funding of small businesses with a high-growth potential.
The Wellcome Trust has awarded £4.3 million to researchers at St George’s, University of London to investigate a new class of drugs for asthma and allergies.
Clavis Pharma ASA, a Norwegian company that specialises in lipid-based delivery of pharmaceutical agents, achieved an endorsement of its technology with a placement of new shares worth NOK 129 million (€14.3 million).
The Swiss specialty biopharmaceutical company, Lumavita AG, has topped up a recent Series A funding round with CHF 6 million, bringing the total amount raised for commercialising its lead antibiotic product to CHF 24 million.
Pharming Group NV has expanded its equity by negotiating the conversion of some of its convertible debt into shares and by issuing about one million new shares from a stand-by equity facility.
Allergy Therapeutics Plc is proposing to raise up to £22.4 million in a private share placement which would give a group of South American investors up to 49.65% of the group’s enlarged share capital.
A British medical discovery company with 25 employees, a history of losses and no products under clinical development is about to raise £50 million through a share sale on Britain’s junior stock market